Disseminated Fungal Infections  in a Kidney Graft Transplant Recipient: Case Report and Literature Review. by Kabinga, Samuel et al.
 International Journal of Sciences: 
Basic and Applied Research 
(IJSBAR) 
 
ISSN 2307-4531 
(Print & Online) 
 
http://gssrr.org/index.php?journal=JournalOfBasicAndApplied 
--------------------------------------------------------------------------------------------------------------------------- 
Disseminated Fungal Infections in a Kidney Graft 
Transplant Recipient: Case Report and Literature Review  
Dr. Samuel Kabingaa*, Dr. Marybeth Maritimb, Dr. Daniel Zurielc, Dr. John  
Ngigid, Prof. Seth  McLigeyoe 
a University of Nairobi, College Of Health Sciences, School of Medicine, P.O. BOX 30197 Postcode 00100 
Nairobi, Kenya 
b Kenyatta National Hospital, P.O. BOX 20723 Postcode 00202 Nairobi, Kenya 
 
 
Abstract 
We present a 61-year-old male, retired driver and a farmer from rural Kenya, East Africa, who had end-stage 
renal disease for 2 years with  a background of  diabetes mellitus and hypertension.  He was on haemodialysis 
since September 2011. He got kidney graft transplant from a living-related donor in October 2013. Six  months 
later, presented with subcutaneous swellings on lower limb and trunk, for 2 months which were identified to be 
Aspergillosis and  Mucormycosis. The history, clinico-laboratory picture and brief  management are given. A 
review of literature on fungal infections in kidney graft recipients is also presented. 
Fungal infections are an important cause of morbidity and mortality in renal transplant recipients. The risk 
factors and the causative agents differ depending on the period after the kidney transplant and the incidence 
varies depending with the geographical area. The emerging fungal infections and paucity of data regarding their 
management pose a challenge to the transplant physicians.  
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1. Introduction  
In this paper we are going to describe the case of J.G.M, he is 61 year-old male, retired driver, farmer from rural 
Kenya, known with diabetes mellitus for 17 years, hypertensive for six years, with subsequent end-stage kidney 
failure and was on renal replacement therapy for 2 years.  During this time, he suffered from cytomegalovirus 
disease (twice) and hepatitis B virus infection. He got kidney graft transplantation from living-related donor in 
October 2013.  Since transplantation, he had been on oral mycophenolic acid 720 mg twice daily, cyclosporin  
200mg  twice daily, prednisone 20mg once daily, pantoprazole 40mg  once daily, isoniazid 300 mg daily, co-
trimoxazole 960 mg  daily, pyridoxine 25 mg  daily, lamivudine 150 mg orally daily, hydrallazine 50mg thrice 
daily, metoprolol 100mg  daily, mixed insulin (30/70)  24 units  in morning, 12 units in the evening with soluble 
insulin 12 units  lunch time. 
He presented with subcutaneous swellings on left thigh, left anterior abdominal wall, left parasternal and right 
anterior cervical region swelling for 2 months and lower limbs swelling, more on the left than right. 
Examination revealed an elderly, sick-looking man, not pale, not icteric, not cyanosed, no oral thrush, right 
posterior cervical triangle lymph node enlargement, bilateral  distal legs   and asymmetrical bipedal oedema.  
Blood pressure : 140/70 mmHg  Pulse rate: 88 beats/minute  
Respiratory rate: 14breaths/minute  Temperature:36.8˚C. 
Respiratory system examination revealed a mid  left sternal healing surgical incision, others findings were 
unremarkable. Abdominal examination revealed healed surgical scar at the right iliac.  Three subcutaneous 
nodular swellings, largest measures about 4cm in diameter. Mobile, non-tender with no skin colour changes. No 
palpable liver of spleen abdominally. No bruits. Cardiovascular system findings were unremarkable. 
Musculoskeletal examination revealed  healing surgical incision on the anterior mid thigh on the left, three 
nodular swellings on the lateral aspect of mid thigh, largest about 2 cm in diameter. Non tender, mobile, no skin 
changes. Femoral, popliteal, posterior tibial pulses present, right dorsalis pedis present. Left  not dorsalis pedis 
not assessed. Asymmetric mild oedema of the feet, hyperpigmented patched over the sole of left foot and toes. 
Very tender left foot. Mr. J.G.M was admitted and management started. He however developed progressive 
renal dysfunction and, with progressive anaemia and respiratory problems.  
 
Figure 1:  Left thigh nodular swellings 
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A      B 
Figure 2: Chest radiographs at admission and a month later  (A at admission, B 3 weeks later) 
He had several complete blood counts tests, whose results ranged from leucocytosis with neutrophilia and 
normal lymphocyte counts to normal total white blood cells counts with mild to moderate anaemia. (Leucocytes 
8.79 – 25.4 X109/L ( 4 – 11), Neutrophils  75.1 – 92.0% (40-70), Lymphocytes 3.24 – 20% (20-40), 
Platelets 65.5 – 470 X109/L (150 -450), haemoglobin  6.88 – 10.7 g/dL (14 -18)). Kidney function tests results 
ranged from hyponatraemia to normal sodium level, naormal potassium levels and high urea and creatinine. 
(119 – 140  (135-145 mmol/L), Potassium 3.92 – 6.02 (3.5 – 5.0 mmol/L), Urea 8.1 – 38.9 (6.0 – 7.2 mmol/L) 
Creatinine, 125 – 408 (60 -110 µm/L))  
Cyclosporine plasma trough levels during the hospital stay were between 101.5 -141.5 ng/mL(100 – 400ng/mL)  
 
   A       B 
Figure 3: Gross appearance (A)  and histology of the excisional biopsy from the neck lesion (B) 
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2. Microbiologic and histologic findings 
2.1 Abdominal wall tissue and pus 
The wet preparation was negative for organisms and negative Ziel Neelsen  staining for acid-alcohol fast 
bacillus. Fungal culture grew Aspergillus spp with no bacterial growth obtained. Histology revealed non-septate 
hypae and yeast form reminiscent of Mucormycosis 
2.2 Right cervical node and pus 
The gram stain was negative for organisms. Ziel Neelsen stain was negative for acid-alcohol fast bacillus and no 
bacterial  growth was obtained on culture. Histoliogy revealed septate fungal hypae, with acute branching  
consistent with Aspergillus spp. 
2.3 Sternal and Left thigh lesion biopsies 
Histology : large septate fungal hyphae with spores among the necrotic debris consistent with Mucormycosis.   
He was planned to receive liposomal amphotericin B  300mg  intravenous infusion once daily for 4 weeks, then,  
step down treatment with posaconazole 400mg orally twice daily for 8 weeks. Amoxylcillin-clavulanate  1g 
orally twice daily for 7 days. Tramadol 50 mg orally thrice daily. Plasma level of cycloporin  after every  2 days 
while on the above,  serum calcium , phosphate, magnesium, urea, electrolytes and creatinine, and Urinalysis  
assays on  alternate day while on amphotericin B.  
He was to continue with mycophenolic acid 720 mg PO  BD, cyclosporine 100mg  PO BD, Prednisone 10mg 
PO OD, pantoprazole 40mg PO BD, co-trimoxazole 960 mg PO OD, pyridoxine 50 mg PO OD, lamivudine 150 
mg PO OD, hydrallazine 50mg PO TID, metoprolol  50mg PO OD, mixed insulin 24 u AM/22 u PM  and 
soluble insulin 12 u lunch time.  
3. Discussion and Literature Review 
Fungal infections can be classified as endemic or opportunistic. The endemic mycoses are infections caused by 
fungal organisms that are not part of the normal human microbial flora and are acquired from environmental 
sources. Opportunistic mycoses are caused by organisms that commonly are components of the normal human 
flora and whose ubiquity in nature renders them easily acquired by the immunocompromised host. For clinical 
discussions, fungal infections can be classified as yeast, mold, and dimorphic fungus.  
Tissue invasion by fungi occurs most frequently in the setting of immunosuppression associated with therapy for 
hematologic malignancies, hematopoietic cell transplantation, or solid organ transplantation. Invasive fungal 
infections are a major complication and an important cause of morbidity and mortality among solid organ 
transplant recipients. Their diagnosis is difficult and their prognosis is often pejorative. In organ transplant 
recipients, infections can result from net state of immunosuppression. Cytomegalovirus infection appears to be a 
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predisposition [1]. Inhibition of  phagocyte nicotinamide adenine dinucleotide phosphate (NADPH) oxidase 
activation, a key component in host defense against filamentous fungi, inhibit macrophage  phagocytosis and 
killing and  suppressed  functional T-cell responses are factors which render the host susceptible to the infection 
and dissemination of established infection. 
Mucormycosis is a fungal infection owing to organisms in the order Mucorales and belonging to the general 
class of Zygomycetes. It is the third most-common invasive, fungal infection; after aspergillosis and candidiasis. 
It is usually found in soil, bread molds, decayed fruits, and vegetables, and also can be cultured from the nasal 
cavity, the throat, the oral cavity, and the stools of healthy patients. Everybody is exposed to this infection and 
inhales the spores; the nasal ciliary system transports these spores down in the pharynx where it is finally 
cleared in the gastrointestinal tract. The spores inhaled by the lungs are cleared by the phagocytes [2]. 
Aspergillosis is the collective term used to describe all disease entities caused by any one of ~35 pathogenic and 
allergenic species of Aspergillus. Mucormycosis most often occurs late, >3 months after transplantation, 
although cases occurring early have been observed [3]. 
Zygomycosis (mucormycosis) is an invasive  opportunistic fungal infection. It is an angio-invasive mycosis with 
high morbidity and mortality rates which mainly affects immunocompromised patients. Disease may manifest as 
rhino-orbital-cerebral, pulmonary, cutaneous, gastrointestinal, or disseminated forms [1]. Diabetes mellitus, 
immunodeficiency, neutropenia, and malignancy are the main underlying conditions. Predisposition of patients 
with diabetic ketoacidosis to  mucormycosis is caused in part by  increased free serum iron in the setting of  
acidaemia [4]. Predisposition to  mucormycosis of  patients treated with deferoxamine [5]  is  due to  
deferoxamine’s role as a siderophore, which  specifically delivers iron to the aetiological fungi [6].   
Invasive fungal infections in renal transplant recipients have been reported months after transplantation. The 
prolonged corticosteroid and immunosuppressive therapy are the main risk factors. Renal failure, graft rejection, 
broad spectrum antibiotics, cytomegalovirus infection,   neutropenia and dialysis [7] are other predispositions.  
In the Transplant-Associated Infection Surveillance Network (TRANSNET),   a consortium of 23 USA 
transplant centers, Pappas et al. reported a prevalence of 2.3% of invasive fungal diseases in solid organ 
transplantation, with a mortality rate approaching 50% [8]. Among kidney transplant recipients Petrikkos et al. 
found a prevalence range between 0.2% to 1.3% [9]. 
Mr J.G.M. had diabetes, was on immunosuppressive treatment with prednisone, mycophenolate mofetil, and 
cyclosporine which are risk factors for mucormycosis and aspergillosis. He had also had suffered from CMV 
disease which put him at risk for the invasive mycoses. 
Conventional histopathology depends on abundance and morphology of the fungi as well as on the skills of the 
personnel, and usually shows an accuracy of 80 %. Polymerase Chain Reaction  assays targeting fungal 
ribosomal genes to identify Mucorales at least at genus level increase sensitivity, allow a rapid identification as 
well as detection of double mold infections [10]. For Mr. J.G.M, histology and culture revealed both 
Mucormycosis and Aspergillosis. 
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Invasive mucormycosis  in patients with acute leukemia and allogeneic stem cell transplant recipients treated 
with antifungal monotherapy is associated with high mortality rates of 44-49%. [11,12,13]. Among the available 
antifungals, amphotericin B (AmB) formulations and posaconazole demonstrated the most promising in vitro 
activities against  Mucorales [14,15] and their combination displays synergistic in vitro activity [16,17].  
According to the American Thoracic Society (ATS) and the Infectious Diseases Society of America (IDSA) 
three classes of antifungal agents are available for the treatment of aspergillosis: polyenes, azoles, and 
echinocandins. Historically, amphotericin B deoxycholate was the major antifungal drug used in patients with 
invasive aspergillosis [18]. Currently, the drug of choice for invasive aspergillosis is voriconazole [19]. Lipid 
formulations of amphotericin B are also used [20]. Echinocandins have activity against Aspergillus spp, but 
have a limited role because they have not been studied adequately for initial treatment of invasive aspergillosis. 
Posaconazole has comparable efficacy to voriconazole against Aspergillus species [21]. Apergillus resistant to 
voriconazole and failure of posaconazole in kidney transplant recipients with invasive infection  with resultant 
mortality has been reported in a centre in the Netherlands [22].  
Mucorales are not susceptible to voriconazole and echinocandins, and as mucormycosis often mimics 
aspergillosis, it is extremely important to have a precise diagnostic to correctly manage the patient. The reversed 
halo sign on chest computed tomography has been associated to mucormycosis in neutropenic patients, but is 
not pathognomonic. Direct fungal identification is crucial. Treatments include lipid formulations of 
amphotericin B, and especially liposomal amphotericin B at high doses (5-10 mg/kg/day), are the standard 
treatment, combined with surgery and control of favoring factors. The prognosis is poor, and any delay in the 
initiation of therapy may impact on outcome. [23]. The treatment of mucormycosis consists of surgical 
debridement, use of antifungal drugs with amphotericin B and posaconazole, and reversal of underlying risk 
factors, when possible. Mortality rates, although lower than in other forms of the disease, are significant, 
ranging from 4% to 10% when the infection is localized [24]. In renal transplant recipients, early diagnosis and 
combined surgical debridement and parenteral liposomal amphotericin-B along with reduction of 
immunosuppression improve the patient survival [25].  For Mr. J.G.M, reduction of immunosuppression  would 
have resulted to graft loss by rejection while treatment with amphotericin B would have resulted in graft 
dysfunction. Concerns with treatment with amphotericin B and posaconazole for Mr. J.G.M. included drugs 
interactions, drugs toxicity especially nephrotoxicity, and cost for less toxic liposomal amphotericin B. 
Reduction of immunosuppressants would have led to rejection of the kidney graft, and return to dialysis. 
Hyperbaric oxygen is a potentially significant adjunct in the treatment of invasive fungal infections. Evidence 
on its usefulness as a standard of care in these infections is still lacking. The value of HBO in patients should be 
considered on an individual basis [26]. 
4. Conclusion 
Cutaneous mucormycosis should be considered in the differential diagnosis when a kidney transplant recipient 
develops erythema-nodosum-like lesions with panniculitis. Treatment of invasive fungal infections is a difficult 
balancing act in this group of patients. 
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